Misplaced Pages

Nusinersen: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 20:57, 31 December 2016 editOceanflynn (talk | contribs)Autopatrolled, Extended confirmed users55,181 edits duplication← Previous edit Revision as of 22:18, 31 December 2016 edit undoJytdog (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers187,951 edits construction; MEDMOS sectionsNext edit →
Line 1: Line 1:
{{under construction}}
'''Nusinersen''' (formerly, IONIS-SMN<sub>Rx</sub>, ISIS-SMN<sub>Rx</sub>), marketed as Spinraza,<ref>{{cite web|url=http://smanewstoday.com/2016/11/01/regulatory-applications-sma-therapy-nusinersen-accepted-us-fda-eu-ema |title=Regulatory Applications for SMA Therapy Nusinersen Accepted in US, EU |publisher=BioNews Services, LLC|date= |accessdate=2016-11-15}}</ref> is the first drug approved by the U.S. ] for use in treating ] (SMA), a rare pediatric disease. Nusinersen is a proprietary ] that modulates ] of the '']'' gene, functionally converting it into '']'' gene. It was developed by ] and licensed to ] for a $75 million license fee,<ref name="genengnews_2016">{{citation |url=http://www.genengnews.com/gen-news-highlights/biogen-shells-out-75m-to-develop-ionis-nusinersen-after-positive-phase-iii-results/81253027 |date=August 1, 2016 |title=Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results |accessdate=December 31, 2016}}</ref> with initial financial support from SMA Foundation and Cure SMA. '''Nusinersen''' (formerly, IONIS-SMN<sub>Rx</sub>, ISIS-SMN<sub>Rx</sub>), marketed as Spinraza,<ref>{{cite web|url=http://smanewstoday.com/2016/11/01/regulatory-applications-sma-therapy-nusinersen-accepted-us-fda-eu-ema |title=Regulatory Applications for SMA Therapy Nusinersen Accepted in US, EU |publisher=BioNews Services, LLC|date= |accessdate=2016-11-15}}</ref> is the first drug approved by the U.S. ] for use in treating ] (SMA), a rare pediatric disease. Nusinersen is a proprietary ] that modulates ] of the '']'' gene, functionally converting it into '']'' gene. It was developed by ] and licensed to ] for a $75 million license fee,<ref name="genengnews_2016">{{citation |url=http://www.genengnews.com/gen-news-highlights/biogen-shells-out-75m-to-develop-ionis-nusinersen-after-positive-phase-iii-results/81253027 |date=August 1, 2016 |title=Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results |accessdate=December 31, 2016}}</ref> with initial financial support from SMA Foundation and Cure SMA.


== Status == == Medical use==
The drug is approved for use in all types of spinal muscular atrophy regardless of age and disease stage. It is administered directly to the ] using ] injection once every 4 months.<ref>{{Cite news|url=http://www.wsj.com/articles/surprise-drug-approval-is-holiday-gift-for-biogen-1482856447|title=Surprise Drug Approval Is Holiday Gift for Biogen|last=Grant|first=Charley|date=2016-12-27|work=|newspaper=Wall Street Journal|issn=0099-9660|access-date=2016-12-27|via=}}</ref> The drug is approved for use in all types of spinal muscular atrophy regardless of age and disease stage. It is administered directly to the ] using ] injection once every 4 months.


==Side effects==

==Pharmacology==

==History==

==Society and culture==



<ref>{{Cite news|url=http://www.wsj.com/articles/surprise-drug-approval-is-holiday-gift-for-biogen-1482856447|title=Surprise Drug Approval Is Holiday Gift for Biogen|last=Grant|first=Charley|date=2016-12-27|work=|newspaper=Wall Street Journal|issn=0099-9660|access-date=2016-12-27|via=}}</ref>


Nusinersen has ] designation in the ] and the ].<ref>{{cite web|url=http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6236 |title=nusinersen |publisher=NHS New Drugs Online Database |date= |accessdate=2016-05-14}}</ref> Nusinersen has ] designation in the ] and the ].<ref>{{cite web|url=http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6236 |title=nusinersen |publisher=NHS New Drugs Online Database |date= |accessdate=2016-05-14}}</ref>

Revision as of 22:18, 31 December 2016

page is in the middle of an expansion or major revampingThis article or section is in a state of significant expansion or restructuring. You are welcome to assist in its construction by editing it as well. If this article or section has not been edited in several days, please remove this template.
If you are the editor who added this template and you are actively editing, please be sure to replace this template with {{in use}} during the active editing session. Click on the link for template parameters to use. This article was last edited by Jytdog (talk | contribs) 8 years ago. (Update timer)

Nusinersen (formerly, IONIS-SMNRx, ISIS-SMNRx), marketed as Spinraza, is the first drug approved by the U.S. Food and Drug Administration for use in treating spinal muscular atrophy (SMA), a rare pediatric disease. Nusinersen is a proprietary antisense oligonucleotide that modulates alternate splicing of the SMN2 gene, functionally converting it into SMN1 gene. It was developed by Ionis Pharmaceuticals and licensed to Biogen for a $75 million license fee, with initial financial support from SMA Foundation and Cure SMA.

Medical use

The drug is approved for use in all types of spinal muscular atrophy regardless of age and disease stage. It is administered directly to the central nervous system using intrathecal injection once every 4 months.


Side effects

Pharmacology

History

Society and culture

Nusinersen has orphan drug designation in the United States and the European Union.

Biogen paid a $75 million license fee to Ionis Pharmaceuticals in August 2016, "after exercising its option to develop and commercialize nusinersen globally" The drug was accepted as a FDA's priority review drug because of a successful 2015 clinical trial involving 82 infants in which "40 percent of babies on the drug reached milestones such as sitting, crawling and walking." According to the New York Times, Spinraza, "will be among the most expensive drugs in the world", with an estimated cost $750,000 in the first year of treatment and "about $375,000 annually after that." Peak annual sales of nusinersen "could reach around $1.5 billion, triggering up to $150 million in additional milestone payments and a royalty percentage up to the mid-teens."

References

  1. "Regulatory Applications for SMA Therapy Nusinersen Accepted in US, EU". BioNews Services, LLC. Retrieved 2016-11-15.
  2. ^ Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results, August 1, 2016, retrieved December 31, 2016
  3. Grant, Charley (2016-12-27). "Surprise Drug Approval Is Holiday Gift for Biogen". Wall Street Journal. ISSN 0099-9660. Retrieved 2016-12-27.
  4. "nusinersen". NHS New Drugs Online Database. Retrieved 2016-05-14.
  5. ^ Katie Thomas (December 30, 2016), Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval, New York Times, retrieved December 31, 2016 {{citation}}: Italic or bold markup not allowed in: |publisher= (help)
  6. Cory Renauer (October 5, 2016), Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc., retrieved December 31, 2016
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: